Article thumbnail

Additive Effect of rPb27 Immunization and Chemotherapy in Experimental Paracoccidioidomycosis

By Viviane C. Fernandes, Estefânia M. N. Martins, Jankerle N. Boeloni, Juliana B. Coitinho, Rogéria Serakides and Alfredo M. Goes


Paracoccidioidomycosis, PCM, the major systemic mycosis in Latin America, is caused by the termally dimorphic fungus Paracoccidioides brasiliensis and requires extended periods of chemotherapy with a significant frequency of relapsing disease. The search for new alternatives of treatment is necessary. rPb27 is an antigenic protein from P. brasiliensis that already showed a significant protective activity as a vaccine for PCM in experimental models. The cDNA of rPb27 was subcloned into a pET-DEST 42 plasmid, expressed in E. coli with a his-tag and purified by affinity chromatography. Immunization with this recombinant protein and chemotherapy were used together in an attempt to improve treatment of PCM. For this, BALB/c mice were challenged with pathogenic P. brasiliensis strain and after immunized with rPb27, in the presence of Corynebacterium parvum and Al(OH)3, some groups were also treated with fluconazole. After 40 days of treatment, the combined drug/rPb27 administration controlled PCM in the liver and spleen, with long lasting protection, and largely preserved tissues structures of these organs. Additionally, in the lungs after 40 days of treatment there was a significant reduction in the fungal load and size of lesions. At the same time, the levels of TNF-α were higher than infected-only mice. Moreover, significant levels of anti-rPb27 specific IgG1, IgG2a and IgG2b isotypes were detected in the sera of mice immunized with rPb27 fluconazole treated or not. These results showed an additive protective effect of rPb27 immunization and chemotherapy, suggesting that an rPb27-based vaccine can be used to enhance PCM antifungal treatment

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). [Guidelines in paracoccidioidomycosis].
  2. (2003). [Paracoccidioidomycosis: a clinical and epidemiological study of 422 cases observed in Mato Grosso do Sul]. Rev Soc Bras Med Trop 36: 455–459.
  3. (2008). Additive effect of P10 immunization and chemotherapy in anergic mice challenged intratracheally with virulent yeasts of Paracoccidioides brasiliensis.
  4. (2003). Antifungal agents: mechanisms of action.
  5. (2009). Case of recurrent Paracoccidioidomycosis: 25 years after initial treatment.
  6. (2004). Central nervous system paracoccidioidomycosis: clinical features and laboratorial findings.
  7. (1993). Cerami A
  8. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
  9. (2003). Combined use of Paracoccidioides brasiliensis recombinant 27-kilodalton and purified 87-kilodalton antigens in an enzyme-linked immunosorbent assay for serodiagnosis of paracoccidioidomycosis.
  10. (2003). Disseminated paracoccidioidomycosis: correlation between clinical and in vitro resistance to ketoconazole and trimethoprim sulphamethoxazole.
  11. (1977). DNA sequencing with chainterminating inhibitors.
  12. (1989). Dynamic, structural, and regulatory aspects of lambda sitespecific recombination.
  13. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
  14. (2004). Fatal disseminated paracoccidioidomycosis in a two-year-old child. Rev Inst Med Trop Sao Paulo
  15. (2010). HSP65 DNA as therapeutic strategy to treat experimental paracoccidioidomycosis.
  16. (1996). Immunological characterization of a recombinant 27-kilodalton antigenic protein from Paracoccidioides brasiliensis.
  17. (2000). Interferon-gamma and tumor necrosis factor-alpha determine resistance to Paracoccidioides brasiliensis infection in mice.
  18. (2005). Microbiology of systemic fungal infections.
  19. (1996). Molecular cloning, nucleotide sequencing, and characterization of a 27-kDa antigenic protein from Paracoccidioides brasiliensis.
  20. (2005). Paracoccidioides brasiliensis, paracoccidioidomycosis, and antifungal antibiotics.
  21. (2008). Paracoccidioides brasiliensis: chemical and molecular tools for research on cell walls, antifungals, diagnosis, taxonomy.
  22. (2006). Peptide immunization as an adjuvant to chemotherapy in mice challenged intratracheally with virulent yeast cells of Paracoccidioides brasiliensis.
  23. (2004). Protective immunity induced in mice by F0 and FII antigens purified from Paracoccidioides brasiliensis.
  24. (1995). Pulmonary paracoccidioidomycosis in resistant and susceptible mice: relationship among progression of infection, bronchoalveolar cell activation, cellular immune response, and specific isotype patterns.
  25. RoqueBarreira MC () Immunological basis for the gender differences in murine Paracoccidioides brasiliensis infection PLoS
  26. (1976). The granulomatous inflammatory response. A review.
  27. Tresoldi AT (2004) Paracoccidioidomycosis in children: clinical presentation, follow-up and outcome. Rev Inst Med Trop Sao Paulo
  28. (1998). Use of the 27-kilodalton recombinant protein from Paracoccidioides brasiliensis in serodiagnosis of paracoccidioidomycosis.
  29. (2004). Viability of yeast form cells of Paracoccidioides brasiliensis after sonication.